Daniel Weinstein is a seasoned business development leader in the Cell & Gene Therapy (CGT) and Advanced Therapies sector, bringing over 20 years of experience spanning CDMO operations, clinical development, and commercial strategy. He specializes in building and executing growth strategies that connect innovative biotech companies with integrated development and manufacturing solutions.

At MedTherapy, Daniel focuses on expanding global CDMO partnerships by aligning client clinical and commercial goals with MedTherapy’s end to end capabilities across R&D, pre clinical development, viral vector manufacturing, and GMP cell therapy production.

Prior to MedTherapy, Daniel held senior business development roles at leading CGT organizations including Kytopen, Cytiva, Cellares, and NYBC Enterprises, where he consistently drove pipeline growth, secured strategic partnerships, and supported launch of disruptive technologies. His work has included structuring complex collaborations, advising biotech companies on clinical development pathways, and integrating CDMO service offerings to accelerate time to clinic.

Daniel’s expertise is grounded in a deep technical foundation developed at PCT/Minaris Advanced Therapies, where he supported and led over 40 cell and gene therapy clinical programs across process development, manufacturing, CMC, and regulatory strategy. This unique combination of scientific and commercial experience enables him to effectively translate client needs into actionable, scalable CDMO solutions.

As an active member of ASGCT, ISCT, SITC, ASTCT, and ASH, he is passionate about advancing innovative therapies by forging strategic partnerships that improve patient access worldwide.